The chemotherapy regimen for bone metastases from lung adenocarcinoma is mainly a two-drug combination based on cisplatin. The two-drug combination can be pemetrexed plus cisplatin, gemcitabine plus cisplatin or docetaxel plus cisplatin, or a regimen of vincristine plus cisplatin. On top of this, anti-tumor angiogenic drugs, such as bevacizumab or recombinant human vascular endothelial inhibitor, which are two anti-tumor angiogenic drugs, can be added, and local radiotherapy can be done for bone metastases, which helps to relieve pain and reduce bone destruction, and with zoledronic acid once a month anti-bone metastasis treatment. In conclusion, the chemotherapy regimen for bone metastasis of lung adenocarcinoma is a two-drug combination regimen based on cisplatin, on top of which anti-tumor angiogenic drugs and zoledronic acid can be used for symptomatic treatment, and local radiotherapy can be added on top of that to reduce symptoms.